サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1693361

神経線維腫症治療の世界市場レポート 2025年

Neurofibromatosis Treatment Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円
神経線維腫症治療の世界市場レポート 2025年
出版日: 2025年03月04日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

神経線維腫症治療の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR13.2％で245億4,000万米ドルに成長します。予測期間の成長は、研究開発と医薬品開発、遠隔医療と遠隔モニタリング、患者教育とサポート、償還政策に起因します。予測期間の主な動向には、視力リハビリテーションサービス、共同ケアモデル、データ分析とAI、視神経補綴物とインプラントが含まれます。

ヘルスケア支出の増加が神経線維腫症治療市場の拡大を牽引すると予想されます。ヘルスケア支出には、医療、予防対策、公衆衛生イニシアチブ、リハビリテーション、地域保健活動、健康リサーチに関連するすべての費用が含まれます。手術、生検、MRIやCTスキャンなどの画像検査など、さまざまな医療処置を伴う神経線維腫症治療を進める上で重要な役割を果たしています。さらに、ヘルスケア支出は、一般医療や神経線維腫症治療のようなサービスを支えています。例えば、2024年5月、英国の政府機関Office for National Statisticsは、2022～2023年にかけての総ヘルスケア支出は5.6％増加すると報告しました。このように、ヘルスケア支出の増加が神経線維腫症治療市場の成長を促進しています。

研究開発（R&D）への注目の高まりは、神経線維腫症治療市場の成長を加速させると予想されます。R&D活動とは、新製品、新技術、新プロセスの創出を目的とした体系的な研究や革新的なプロジェクトに投資する組織の取り組みを指します。研究開発活動の急増は、競争力を維持し、消費者の需要に対応し、技術革新に適応するためのイノベーションの必要性によってもたらされています。神経線維腫症の治療開発に重点が置かれていることから、研究開発活動が活発化しており、主要企業はこの疾患の根本的なメカニズムの解明や新たな治療法の模索に注力しています。例えば、製薬業界を代表する欧州の業界団体である欧州製薬団体連合会（EFPIA）は2023年6月、欧州における医薬品研究開発費が2022年に495億米ドル（445億ユーロ）に達し、2021年の465億米ドル（425億ユーロ）から6.45％増加したと報告しました。このため、研究開発重視の高まりが神経線維腫症治療市場の拡大を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の神経線維腫症治療市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界の神経線維腫症治療市場：成長率分析
  • 世界の神経線維腫症治療市場の実績：規模と成長、2019～2024年
  • 世界の神経線維腫症治療市場の予測：規模と成長、2024～2029年、2034年
  • 世界の神経線維腫症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の神経線維腫症治療市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 神経線維腫症1型（NF1）
  • 神経線維腫症2型（NF2）
  • シュワン細胞腫症
  • 世界の神経線維腫症治療市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
  • 薬物療法
  • 手術
  • 放射線治療
  • その他
  • 世界の神経線維腫症治療市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院
  • クリニック
  • その他
  • 世界の神経線維腫症治療市場：神経線維腫症1型（NF1）のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 外科的介入
  • 症状管理のための薬物療法
  • 遺伝カウンセリング
  • 世界の神経線維腫症治療市場：神経線維腫症2型（NF2）のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 外科的介入
  • 放射線治療
  • 症状管理のための薬物療法
  • 世界の神経線維腫症治療市場：シュワン細胞腫症のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 外科的介入
  • 疼痛管理療法
  • 遺伝カウンセリング

第7章 地域別・国別分析

  • 世界の神経線維腫症治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の神経線維腫症治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 神経線維腫症治療市場：競合情勢
  • 神経線維腫症治療市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • GSK PLC
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Vertex Pharmaceuticals Inc.
  • Dr. Reddy's Laboratories
  • BioMarin Pharmaceutical
  • Allergan
  • BeiGene Ltd.
  • BioXcel Therapeutics Inc.
  • Blueprint Medicines Corp.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 神経線維腫症治療市場2029：新たな機会を提供する国
  • 神経線維腫症治療市場2029：新たな機会を提供するセグメント
  • 神経線維腫症治療市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r28601

Neurofibromatosis treatment involves addressing a genetic disorder that causes tumors to develop on nerve tissue, which can occur anywhere in the body, including the brain, spinal cord, and peripheral nerves. The treatment aims to manage symptoms, slow disease progression, and prevent complications associated with the condition.

Neurofibromatosis treatment encompasses approaches tailored for neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis. Neurofibromatosis type 1 (NF1) is a hereditary disorder characterized by the development of tumors on nerves throughout the body. Various treatment modalities such as medications, surgical interventions, radiation therapy, and other specialized approaches are utilized by a range of end-users, including hospitals, clinics, and other medical facilities.

The neurofibromatosis treatment market research report is one of a series of new reports from The Business Research Company that provides neurofibromatosis treatment market statistics, including neurofibromatosis treatment industry global market size, regional shares, competitors with a neurofibromatosis treatment market share, detailed neurofibromatosis treatment market segments, market trends and opportunities and any further data you may need to thrive in the neurofibromatosis treatment industry. This neurofibromatosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neurofibromatosis treatment market size has grown rapidly in recent years. It will grow from $13.09 billion in 2024 to $14.96 billion in 2025 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to aging population, advancements in ophthalmology, patient-centered care, global healthcare access.

The neurofibromatosis treatment market size is expected to see rapid growth in the next few years. It will grow to $24.54 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to research and drug development, telemedicine and remote monitoring, patient education and support, reimbursement policies. Major trends in the forecast period include vision rehabilitation services, collaborative care models, data analytics and ai, optic nerve prostheses and implants.

The growing healthcare expenditure is expected to drive the expansion of the neurofibromatosis treatment market. Healthcare expenditure includes all costs related to medical care, preventive measures, public health initiatives, rehabilitation, community health activities, and health research. It plays a vital role in advancing neurofibromatosis treatment, which involves various medical procedures such as surgeries, biopsies, and imaging tests like MRI and CT scans. Additionally, healthcare spending supports services like general medical care and neurofibromatosis treatment. For example, in May 2024, the Office for National Statistics, a UK-based government agency, reported a 5.6% increase in total healthcare expenditure from 2022 to 2023, compared to a modest 0.9% growth in 2022. Thus, the rise in healthcare expenditure is fueling the growth of the neurofibromatosis treatment market.

The growing focus on research and development (R&D) is expected to accelerate the growth of the neurofibromatosis treatment market. R&D activities refer to the increasing efforts by organizations to invest in systematic studies and innovative projects aimed at creating new products, technologies, or processes. The surge in R&D activities is driven by the need for innovation to maintain competitive edge, address consumer demands, and adapt to technological changes. The emphasis on developing treatments for neurofibromatosis has led to a rise in R&D efforts, with companies focusing on understanding the disease's underlying mechanisms and exploring new treatment options. For instance, in June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a European trade group representing the pharmaceutical industry, reported that pharmaceutical R&D expenditure in Europe reached $49.5 billion (€44.5 billion) in 2022, marking a 6.45% increase from $46.5 billion (€42.5 billion) in 2021. Therefore, the growing emphasis on R&D is driving the expansion of the neurofibromatosis treatment market.

Leading companies in the neurofibromatosis treatment market are advancing the development of innovative drugs and investigational targeted therapies, such as MEK inhibitors, to maintain their competitive edge. MEK inhibitors are a class of targeted therapies that block the MEK enzyme, which is part of the MAPK signaling pathway. This inhibition helps treat cancers and genetic disorders like neurofibromatosis by preventing cell growth and tumor progression. For example, in March 2024, SpringWorks Therapeutics, Inc., a US-based biopharmaceutical company, completed its submission of a new drug application (NDA) to the FDA for Mirdametinib, a treatment aimed at both children and adults with NF1-PN. Mirdametinib is a selective MEK inhibitor designed to target specific pathways responsible for the growth of neurofibromas. The FDA will review the safety and efficacy of this treatment, which could significantly improve the outcomes for individuals suffering from NF1-PN.

In October 2022, Pasithea Therapeutics, a prominent biotechnology company based in the US, completed the acquisition of AlloMek Therapeutics for $1.05 million. This strategic move is set to significantly enhance Pasithea Therapeutics' drug development efforts, with a specific focus on the Central Nervous System (CNS). AlloMek Therapeutics, a pharmaceutical company also based in the US, specializes in the development of treatments for a range of conditions including neurofibromatosis, congenital muscular disease, and catastrophic cardiomyopathy.

Major companies operating in the neurofibromatosis treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Vertex Pharmaceuticals Inc., Dr. Reddy's Laboratories, BioMarin Pharmaceutical, Allergan, BeiGene Ltd., BioXcel Therapeutics Inc., Blueprint Medicines Corp., Genway BioTech, SpringWorks Therapeutics, LGM Pharma LLC, Biotechnica Pharma Global, Affymax Inc.

North America was the largest region in the neurofibromatosis treatment market in 2024. The regions covered in neurofibromatosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurofibromatosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurofibromatosis treatment market consists of revenues earned by entities by providing services such as stereotactic radiosurgery, genetic evaluation, physical therapy and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurofibromatosis treatment market also includes sales of drugs such as selumetinib, bevacizumab and tricyclic antidepressants. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurofibromatosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurofibromatosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurofibromatosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurofibromatosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Neurofibromatosis 1 (NF1); Neurofibromatosis 2 (NF2); Schwannomatosis
  • 2) By Treatment: Medications; Surgery; Radiation Therapy; Other Treatments
  • 3) By End-Users: Hospitals; Clinics; Other End Users
  • Subsegments:
  • 1) By Neurofibromatosis 1 (NF1): Surgical Interventions; Medication for Symptom Management; Genetic Counseling
  • 2) By Neurofibromatosis 2 (NF2): Surgical Interventions; Radiation Therapy; Medication for Symptom Management
  • 3) By Schwannomatosis: Surgical Interventions; Pain Management Therapies; Genetic Counseling
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurofibromatosis Treatment Market Characteristics

3. Neurofibromatosis Treatment Market Trends And Strategies

4. Neurofibromatosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Neurofibromatosis Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Neurofibromatosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Neurofibromatosis Treatment Market Growth Rate Analysis
  • 5.4. Global Neurofibromatosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Neurofibromatosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Neurofibromatosis Treatment Total Addressable Market (TAM)

6. Neurofibromatosis Treatment Market Segmentation

  • 6.1. Global Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Neurofibromatosis 1 (NF1)
  • Neurofibromatosis 2 (NF2)
  • Schwannomatosis
  • 6.2. Global Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Medications
  • Surgery
  • Radiation Therapy
  • Other Treatments
  • 6.3. Global Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Clinics
  • Other End Users
  • 6.4. Global Neurofibromatosis Treatment Market, Sub-Segmentation Of Neurofibromatosis 1 (NF1), By type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Surgical Interventions
  • Medication for Symptom Management
  • Genetic Counseling
  • 6.5. Global Neurofibromatosis Treatment Market, Sub-Segmentation Of Neurofibromatosis 2 (NF2), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Surgical Interventions
  • Radiation Therapy
  • Medication for Symptom Management
  • 6.6. Global Neurofibromatosis Treatment Market, Sub-Segmentation Of Schwannomatosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Surgical Interventions
  • Pain Management Therapies
  • Genetic Counseling

7. Neurofibromatosis Treatment Market Regional And Country Analysis

  • 7.1. Global Neurofibromatosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Neurofibromatosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurofibromatosis Treatment Market

  • 8.1. Asia-Pacific Neurofibromatosis Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurofibromatosis Treatment Market

  • 9.1. China Neurofibromatosis Treatment Market Overview
  • 9.2. China Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurofibromatosis Treatment Market

  • 10.1. India Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurofibromatosis Treatment Market

  • 11.1. Japan Neurofibromatosis Treatment Market Overview
  • 11.2. Japan Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurofibromatosis Treatment Market

  • 12.1. Australia Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurofibromatosis Treatment Market

  • 13.1. Indonesia Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurofibromatosis Treatment Market

  • 14.1. South Korea Neurofibromatosis Treatment Market Overview
  • 14.2. South Korea Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurofibromatosis Treatment Market

  • 15.1. Western Europe Neurofibromatosis Treatment Market Overview
  • 15.2. Western Europe Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurofibromatosis Treatment Market

  • 16.1. UK Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurofibromatosis Treatment Market

  • 17.1. Germany Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurofibromatosis Treatment Market

  • 18.1. France Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurofibromatosis Treatment Market

  • 19.1. Italy Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurofibromatosis Treatment Market

  • 20.1. Spain Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurofibromatosis Treatment Market

  • 21.1. Eastern Europe Neurofibromatosis Treatment Market Overview
  • 21.2. Eastern Europe Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurofibromatosis Treatment Market

  • 22.1. Russia Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurofibromatosis Treatment Market

  • 23.1. North America Neurofibromatosis Treatment Market Overview
  • 23.2. North America Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurofibromatosis Treatment Market

  • 24.1. USA Neurofibromatosis Treatment Market Overview
  • 24.2. USA Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurofibromatosis Treatment Market

  • 25.1. Canada Neurofibromatosis Treatment Market Overview
  • 25.2. Canada Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurofibromatosis Treatment Market

  • 26.1. South America Neurofibromatosis Treatment Market Overview
  • 26.2. South America Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurofibromatosis Treatment Market

  • 27.1. Brazil Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurofibromatosis Treatment Market

  • 28.1. Middle East Neurofibromatosis Treatment Market Overview
  • 28.2. Middle East Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurofibromatosis Treatment Market

  • 29.1. Africa Neurofibromatosis Treatment Market Overview
  • 29.2. Africa Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurofibromatosis Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Neurofibromatosis Treatment Market Competitive Landscape
  • 30.2. Neurofibromatosis Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Neurofibromatosis Treatment Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A.
  • 31.2. Bristol-Myers Squibb Company
  • 31.3. AstraZeneca plc
  • 31.4. GSK PLC
  • 31.5. Takeda Pharmaceutical Company Limited
  • 31.6. Eli Lilly and Company
  • 31.7. Gilead Sciences Inc.
  • 31.8. Amgen Inc.
  • 31.9. Vertex Pharmaceuticals Inc.
  • 31.10. Dr. Reddy's Laboratories
  • 31.11. BioMarin Pharmaceutical
  • 31.12. Allergan
  • 31.13. BeiGene Ltd.
  • 31.14. BioXcel Therapeutics Inc.
  • 31.15. Blueprint Medicines Corp.

32. Global Neurofibromatosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurofibromatosis Treatment Market

34. Recent Developments In The Neurofibromatosis Treatment Market

35. Neurofibromatosis Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Neurofibromatosis Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Neurofibromatosis Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Neurofibromatosis Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer